With CMV in its sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into the clinic.
The post-Pfizer pipeline looks disparate, but the group insists there is a method to its fast-follower approach.
But the group has chosen the tough immuno-oncology space for its third attempt to woo the big players.
Lung cancer approval for the group’s electric fields-based therapy could come this year, but Novocure has broader solid tumour ambitions.
A collaboration this week with the blood testing specialist Capitainer underlines the big pharma’s ambition to have a diagnostic linked with every pipeline project.
The group continues its niche-targeting strategy with abelacimab’s latest pivotal trial.
The gene therapy player survived 2022 relatively unscathed, but big tests remain.
But the current leader, Vaxxinity, will have to convince its doubters if it is to hook a partner.
Nimbus aims to push Tyk2 inhibition to the limit with its more selective project, but others have a similar idea.